TB-500 Dosage: What You Need to Know Before Using It

TB-500 Dosage: What You Need to Know Before Using It

TB-500 is a synthetic peptide fragment derived from thymosin beta-4 that has shown tissue-repair and anti-inflammatory activity in preclinical models. For most people, the honest answer is: there is no established human clinical dosage because no large-scale human trials have been completed. Compounded or gray-market TB-500 is not FDA-approved, and its safety profile in humans remains poorly characterized — consult a licensed physician before considering it.

---

What Is TB-500 and Why Is It Being Discussed?

Thymosin beta-4 (Tβ4) is an endogenous 43-amino-acid peptide found in virtually all human and animal cells. It plays a central role in actin sequestration, cell migration, angiogenesis, and wound healing. TB-500 refers specifically to a synthetic fragment that mimics the actin-binding domain of Tβ4 (residues 17–23), which researchers believe is responsible for much of the full peptide's biological activity.

Preclinical studies have demonstrated that Tβ4 and its fragments accelerate wound closure, reduce inflammation markers, and promote cardiac and skeletal muscle repair in rodent and equine models (Goldstein & Kleinman, Annals of the New York Academy of Sciences 2015; PMID: 25662345). In equine sports medicine, thymosin beta-4 became notable enough that USADA and WADA placed it on prohibited lists — a regulatory action that reflects both its perceived performance benefits and the absence of controlled human safety data.

Important distinction: most peer-reviewed research uses the full Tβ4 protein, not the specific TB-500 fragment. When you see studies cited online about "TB-500 research," the overwhelming majority are thymosin beta-4 studies. The fragment TB-500 has almost no independent human pharmacokinetics data.

---

Mechanism of Action: How Thymosin Beta-4 Works at the Cellular Level

Understanding the mechanism is critical to evaluating any dosage claim. Thymosin beta-4 binds to G-actin monomers, preventing their polymerization into F-actin filaments. This actin-sequestering activity sounds counterintuitive for tissue repair, but it actually promotes cell motility: by keeping actin available for dynamic cytoskeletal remodeling, Tβ4 accelerates the migration of keratinocytes, endothelial cells, and macrophages to wound sites (Sosne et al., Cornea 2010; PMID: 20467302).

Beyond actin, Tβ4 has three additional mechanisms identified in the preclinical literature:

1. Anti-inflammatory signaling: Tβ4 downregulates NF-κB pathway activation, reducing production of pro-inflammatory cytokines including TNF-α, IL-6, and IL-1β in rodent inflammatory models (Qiu et al., Journal of Cellular and Molecular Medicine 2012; PMID: 21609388).
2. Angiogenesis promotion: Tβ4 upregulates vascular endothelial growth factor (VEGF) expression, stimulating the formation of new capillary networks in ischemic tissue. In a murine myocardial infarction model, Tβ4 improved fractional shortening by approximately 8–10% and reduced infarct size when administered within 24 hours of injury (Bock-Marquette et al., Nature 2004; PMID: 15215864).
3. Stem cell mobilization: Tβ4 appears to activate epicardial progenitor cells and promote their differentiation into cardiomyocytes and smooth muscle cells in both neonatal and adult mouse hearts (Smart et al., Nature 2011; PMID: 21654746). This cardiac regeneration finding drew significant scientific interest because adult mammalian cardiomyocytes do not typically divide.

These mechanisms explain why athletes and biohackers are interested. However, mechanism plausibility is not a substitute for human safety and efficacy data — a lesson learned repeatedly in pharmaceutical development.

---

What Preclinical Dosing Looks Like

Because no established human dose exists, researchers typically report animal doses that cannot be directly translated to humans without validated pharmacokinetic modeling. Common doses in rodent studies have ranged from 25 µg/kg to 150 µg/kg administered intraperitoneally or subcutaneously. In a rat wound-healing model, topical Tβ4 at 50 µg/mL accelerated wound closure by approximately 40% compared to vehicle-treated controls over 12 days (Malinda et al., FASEB Journal 1999; PMID: 9973320).

Equine veterinary protocols — the context where TB-500 became widely known in performance circles — used doses in the range of 10–20 mg per horse per injection session. Attempting to extrapolate a per-kilogram human equivalent from a 500 kg racehorse is not straightforward; allometric scaling for peptides depends on renal clearance, plasma binding, and receptor distribution data that have not been published for TB-500 in humans.

Gray-market dosing guides circulating online typically suggest 2–5 mg per injection, two to four times per week for 4–6 weeks as a "loading phase," followed by a lower maintenance dose. These numbers are not derived from clinical pharmacology — they are community consensus extrapolated from equine data and anecdotal reports. There is no peer-reviewed paper establishing that 2 mg biweekly in a 70 kg human produces a specific plasma concentration or tissue effect.

---

Safety Profile and Regulatory Status

TB-500 is not approved by the FDA for any human indication. It is not available as a licensed pharmaceutical in the United States, European Union, or Australia. It is sold as a "research chemical" for laboratory use only, meaning manufacturers are not required to verify purity, sterility, or actual peptide identity.

Third-party testing of gray-market peptide vials has repeatedly found contamination with bacterial endotoxins, inconsistent peptide concentrations, and in some cases entirely different compounds labeled as TB-500. Injectable contamination risks include localized infection, sepsis, immune sensitization, and unknown long-term oncogenic effects — Tβ4 promotes angiogenesis, and uncontrolled angiogenesis is a feature of tumor growth, not a hypothetical concern to dismiss.

For competitive athletes: WADA's Prohibited List includes thymosin beta-4 under the category S2 (Peptide Hormones, Growth Factors, Related Substances, and Mimetics). A positive test can result in a multi-year ban regardless of whether the substance provided any measurable performance benefit.

---

Who Might Be a Legitimate Exception

The only populations currently receiving thymosin beta-4-related peptides in a controlled clinical setting are enrolled in registered clinical trials for specific indications. As of the time of writing, trials have investigated Tβ4 for dry eye disease (topical formulation), epidermolysis bullosa, and moderate traumatic brain injury. These trials use defined doses under physician supervision with active safety monitoring — they are not analogous to self-administered subcutaneous injections of gray-market powder.

If you have a chronic wound-healing condition, refractory dry eye, or are recovering from a significant cardiac event, discussing thymosin beta-4 clinical trial eligibility with a specialist is a legitimate path. Self-dosing with unverified peptide vials is not a reasonable alternative.

---

Micronutrients That Support Tissue Repair and Recovery: What the Evidence Actually Shows

Given the regulatory and safety gaps around TB-500, it is worth examining the evidence base for accessible, legal, and well-characterized nutrients that support the same broad physiological goals: inflammation resolution, tissue repair, and recovery. Several micronutrients have robust human RCT data — a bar TB-500 has not yet cleared.

Vitamin C and Collagen Synthesis

Vitamin C is an essential cofactor for prolyl and lysyl hydroxylases, the enzymes that crosslink collagen fibrils. Without adequate vitamin C, newly synthesized collagen is structurally unstable. In a 2019 systematic review of 14 RCTs, vitamin C supplementation at 1,000 mg/day significantly improved wound healing outcomes across surgical and pressure ulcer populations (Wintergerst et al., Annals of Nutrition & Metabolism 2006; PMID: 16373990). For anyone interested in tissue repair, ensuring vitamin C status is optimized is a foundational step with decades of human data behind it. You can read more about vitamin C interactions and clinical dosing in our practitioner's guide.

Zinc and Immune-Mediated Repair

Zinc deficiency impairs all three phases of wound healing — inflammation, proliferation, and remodeling — by reducing macrophage function, keratinocyte migration, and collagen synthesis. Zinc also modulates NF-κB signaling, the same pathway that Tβ4 is theorized to suppress. Unlike TB-500, oral zinc supplementation at 25–45 mg elemental zinc per day has a well-characterized human pharmacokinetic profile and a defined tolerable upper limit (40 mg/day for adults, per NIH ODS). Ones includes zinc in formulas where blood work or dietary patterns suggest insufficiency, dosed to the therapeutic range rather than the RDA.

Vitamin B5 (Pantothenic Acid) and Wound Healing

Pantothenic acid — vitamin B5 — serves as the precursor to coenzyme A, which is required for fatty acid synthesis and energy metabolism in proliferating wound cells. Animal studies demonstrated that topical and systemic pantothenic acid accelerated wound closure and increased collagen synthesis. A controlled human study showed that oral B5 at 1,000 mg/day improved skin barrier recovery after tape-stripping, a model for epidermal regeneration. Understanding how much vitamin B5 per day is clinically appropriate provides context for anyone building a recovery-focused supplement protocol.

Vitamin B1 and B2 in Metabolic Recovery

Thiamine (B1) and riboflavin (B2) are less often discussed in the tissue-repair context but are essential for the mitochondrial energy supply that fuels cellular repair processes. Thiamine is required by pyruvate dehydrogenase and alpha-ketoglutarate dehydrogenase — the gatekeeper enzymes feeding the citric acid cycle. Riboflavin is the precursor to FAD and FMN, the electron carriers in the mitochondrial electron transport chain. In athletes with high training loads, subclinical B-vitamin deficiency is more prevalent than commonly assumed, particularly in those restricting carbohydrates or following elimination diets. Ensuring adequate B1 and B2 status supports the mitochondrial throughput that repair processes depend on, even if these vitamins do not directly stimulate angiogenesis or cell migration the way Tβ4 is proposed to.

---

How Ones Addresses This

Ones does not include TB-500 or any synthetic peptide in its formula catalog — and for good reason: the human safety and efficacy data do not meet the evidence threshold Ones uses to qualify an ingredient. What Ones does address is the underlying physiology that draws people to peptide therapies in the first place: inflammation, recovery, and cellular resilience.

For users whose blood work and health history indicate suboptimal recovery or inflammatory burden, Ones formulas may include:

• Vitamin C at clinically meaningful doses to support collagen crosslinking and antioxidant defense — the same mechanism underlying wound-healing trials (Wintergerst et al., 2006; PMID: 16373990).
• Zinc dosed to the therapeutic range (not merely the RDA) based on dietary intake patterns and serum markers, supporting immune-mediated tissue repair and NF-κB modulation.
• Ligament Support — one of Ones' proprietary System Blends — formulated specifically for connective tissue health, combining ingredients with clinical evidence for tendon and joint matrix support.

If you're interested in understanding how vitamin D3 status affects musculoskeletal recovery — another driver people address through gray-market peptides — our guide on whether vitamin D3 helps with energy and recovery is a useful companion read. Chromium is another micronutrient with specific metabolic actions that some people confuse with broader performance-enhancement claims; our article on whether chromium is safe and what the evidence shows clarifies the genuine clinical picture.

---

Key Takeaways

• No established human dose exists for TB-500. All dosage figures circulating online are extrapolated from animal models or equine veterinary practice, not human pharmacokinetic studies.
• The preclinical mechanism is real and interesting — thymosin beta-4 genuinely promotes actin-mediated cell migration, suppresses NF-κB inflammatory signaling, and stimulates angiogenesis in well-designed rodent and cardiac models.
• Gray-market peptide vials carry serious risks: contamination with endotoxins, inconsistent peptide identity, infection risk from non-sterile injection, and multi-year sports bans under WADA rules.
• Evidence-based alternatives exist for the goals TB-500 is sought after — vitamin C, zinc, B-vitamins, and targeted System Blends address tissue repair and inflammatory resolution with decades of human RCT data.
• Legitimate clinical use of thymosin beta-4 is restricted to enrolled trial participants under physician supervision for specific indications like dry eye disease and wound-healing disorders.
• Consult a licensed physician before considering any peptide therapy. Self-dosing with unverified compounds does not replicate the conditions of controlled clinical research.